In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
|Articles|February 18, 2019
Saama Unveils New Capabilities for Life Science Analytics Cloud
Advertisement
Saama Technologies, Inc., a data analytics company, launched three new machine learning-based capabilities that add to the existing functionality of its Life Science Analytics Cloud (LSAC). Saama announced the addition of these programs infused with artificial intelligence (AI)-Virtual Assistant/AI, Operational and Financial Risk Mitigation, and Drug Efficacy and Patient Safety Analytics-during the 10th Annual Summit for Clinical Ops Executives (SCOPE) in Orlando.
Read the full release
Advertisement
Related to this article
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, shares what she expects to be at the center of the conversation—from building trust between patients and sites to where AI may and may not have a role in that relationship.
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
2
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
3
How a Platform Approach Can Scale AI’s Impact in Life Sciences
4
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
5